Literature DB >> 17178188

Additional surgical intervention after radical prostatectomy, radiation therapy, androgen-deprivation therapy, or watchful waiting.

Viktor Berge1, Trevor Thompson, Donald Blackman.   

Abstract

OBJECTIVES: The amount of additional surgical procedures that cancer patients undergo following their initial treatment is one means of measuring the impact that cancer and cancer treatment has on their quality of life. In this study we looked for treatment-related differences in the need for additional surgical intervention among men with nonmetastatic prostate cancer within 66 mo of their initial treatment.
METHODS: Data for this study were from the National Cancer Institutes Surveillance, Epidemiology, and End Results (SEER) program and from the Medicare claims database. We searched the claims database for procedure codes indicating artificial urinary sphincter procedures, cystoscopy, urethral dilation, transurethral resection of the prostate (TURP) and bladder-neck incision, bladder irrigation/cystotomy, or nephrostomy.
RESULTS: Of the 12,711 patients in our study, 3940 (31.0%) were initially treated by radical prostatectomy (RP), 3950 (31.1%) by radiation therapy (RT), 1209 (9.5%) by androgen-deprivation therapy (ADT), and 3612 (28.4%) by watchful waiting (WW). The percentage of patients who underwent cystoscopy 6-66 mo after their initial treatment ranged narrowly from 22% to 24% among members of the four treatment groups. In the RP group, 5.2% had artificial urinary sphincter procedures; 6.8% of the RT group, 8.2% of the ADT group, and 10.1% of the WW group had TURP/bladder-neck procedures compared with 3.7% of the RP group; and 12.5-16.2% of members in the four groups had urethral dilation procedures.
CONCLUSIONS: Over one third of prostate cancer patients needed surgical intervention within 66 mo of their initial treatment despite the type of initial treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17178188     DOI: 10.1016/j.eururo.2006.12.012

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  7 in total

1.  Understanding fragmentation of prostate cancer survivorship care: implications for cost and quality.

Authors:  Ted A Skolarus; Yun Zhang; Brent K Hollenbeck
Journal:  Cancer       Date:  2011-10-05       Impact factor: 6.860

2.  The need for, and utilization of prostate-bed radiotherapy after radical prostatectomy for patients with prostate cancer in British Columbia.

Authors:  Scott Tyldesley; Michael Peacock; James W Morris; Alan So; Charmaine Kim-Sing; Jill Quirt; Michael Carter; Tom Pickles
Journal:  Can Urol Assoc J       Date:  2012-04       Impact factor: 1.862

3.  Predictors of Regret among Older Men after Stress Urinary Incontinence Treatment Decisions.

Authors:  Lindsay A Hampson; Anne M Suskind; Benjamin N Breyer; Matthew R Cooperberg; Rebecca L Sudore; Salomeh Keyhani; I Elaine Allen; Louise C Walter
Journal:  J Urol       Date:  2021-12-02       Impact factor: 7.450

4.  Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity.

Authors:  James B Yu; Pamela R Soulos; Jeph Herrin; Laura D Cramer; Arnold L Potosky; Kenneth B Roberts; Cary P Gross
Journal:  J Natl Cancer Inst       Date:  2012-12-14       Impact factor: 13.506

5.  Analysis of urological procedures in men who died from prostate cancer using a population-based approach.

Authors:  Kara Babaian; Matthew Truong; Jeremy Cetnar; Deanna S Cross; Fangfang Shi; Mark A Ritter; David F Jarrard
Journal:  BJU Int       Date:  2012-11-06       Impact factor: 5.588

Review 6.  Penile prosthesis in the management of erectile dysfunction following cancer therapy.

Authors:  Pranav Dadhich; Mark Hockenberry; E Will Kirby; Larry Lipshultz
Journal:  Transl Androl Urol       Date:  2017-11

7.  Transurethral Prostatectomy Before or After External Beam Radiotherapy: Complications and Reoperation Rates.

Authors:  Gabriel Molineros; Amichay Meirovitz; Marc Wygoda; Mohammad Zuaiter; Vladimir Yutkin; Mordechai Duvdevani; Guy Hidas; Ofer N Gofrit
Journal:  Res Rep Urol       Date:  2021-04-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.